Free Trial
NASDAQ:GOSS

Gossamer Bio Q2 2025 Earnings Report

Gossamer Bio logo
$2.82 +0.12 (+4.44%)
Closing price 04:00 PM Eastern
Extended Trading
$2.77 -0.05 (-1.74%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gossamer Bio EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.18
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Gossamer Bio Revenue Results

Actual Revenue
$11.49 million
Expected Revenue
$4.12 million
Beat/Miss
Beat by +$7.37 million
YoY Revenue Growth
N/A

Gossamer Bio Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Gossamer Bio's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Monday, November 3, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Gossamer Bio Earnings Headlines

Gossamer Bio Enters Merger Agreement with Respira
Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
See More Gossamer Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gossamer Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gossamer Bio and other key companies, straight to your email.

About Gossamer Bio

Gossamer Bio (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies. In addition to these clinical-stage assets, Gossamer Bio maintains several earlier-stage programs targeting pathways such as integrin and TGF-β signaling. The company’s R&D efforts are supported by a combination of in-house research capabilities and external collaborations with academic centers and contract research organizations.

Gossamer Bio completed its initial public offering in July 2019 and has since advanced multiple clinical trials across North America and selected international sites. The company is led by President and Chief Executive Officer Thomas A. Whiting, a veteran of the biopharmaceutical industry with over 25 years of drug development experience. Under his leadership, Gossamer Bio continues to build a multidisciplinary management team focused on accelerating the translation of scientific insights into therapeutic candidates.

View Gossamer Bio Profile

More Earnings Resources from MarketBeat